Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Varga

Showing results (241-250 of 297) with videos related to

Pageof 30
Sort By:
JCI Insight|February 17, 2026
A potent inhibitor of PAI-1, MDI-2517, mitigates disease severity in a preclinical systemic sclerosis modelEnming J Su, Pei-Suen Tsou, Mark Warnock, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 31, 2022
Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical TrialDinesh Khanna, Paul Caldron, Richard W Martin, et al.
Chest|December 15, 2025
Systemic Sclerosis-Associated Interstitial Lung Disease: What We Know and How to Incorporate Guidelines into Clinical PracticeAnthony J Esposito, Kavitha C Selvan, Carrie Richardson, et al.
Seminars in Arthritis and Rheumatism|February 24, 2004
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements, James R Seibold, Daniel E Furst, et al.
Iscience|January 1, 2021
Targeting CD38-dependent NAD<sup>+</sup> metabolism to mitigate multiple organ fibrosisBo Shi, Wenxia Wang, Benjamin Korman, et al.
JCI Insight|July 20, 2023
Pansclerotic morphea is characterized by IFN-γ responses priming dendritic cell fibroblast crosstalk to promote fibrosisEnze Xing, Feiyang Ma, Rachael Wasikowski, et al.
Annals of the Rheumatic Diseases|August 9, 2019
Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signaturesShervin Assassi, Xuan Wang, Guocai Chen, et al.
Nature Communications|January 31, 2023
Author Correction: Fibroblast A20 governs fibrosis susceptibility and its repression by DREAM promotes fibrosis in multiple organsWenxia Wang, Swarna Bale, Jun Wei, et al.
Translational Behavioral Medicine|March 31, 2023
Exploring research team members' and trial participants' perceptions of acceptability and implementation within one videoconference-based supportive care program for individuals affected by systemic sclerosis during COVID-19: a qualitative interview studyAmanda Wurz, Kelsey Ellis, Delaney Duchek, et al.
Arthritis and Rheumatism|November 13, 2002
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trialPaul J DeMarco, Michael H Weisman, James R Seibold, et al.
Pageof 30

Showing results (241-250 of 297) with videos related to

Sort By:
Pageof 30
JCI Insight|February 17, 2026
A potent inhibitor of PAI-1, MDI-2517, mitigates disease severity in a preclinical systemic sclerosis modelEnming J Su, Pei-Suen Tsou, Mark Warnock, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 31, 2022
Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical TrialDinesh Khanna, Paul Caldron, Richard W Martin, et al.
Chest|December 15, 2025
Systemic Sclerosis-Associated Interstitial Lung Disease: What We Know and How to Incorporate Guidelines into Clinical PracticeAnthony J Esposito, Kavitha C Selvan, Carrie Richardson, et al.
Seminars in Arthritis and Rheumatism|February 24, 2004
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements, James R Seibold, Daniel E Furst, et al.
Iscience|January 1, 2021
Targeting CD38-dependent NAD<sup>+</sup> metabolism to mitigate multiple organ fibrosisBo Shi, Wenxia Wang, Benjamin Korman, et al.
JCI Insight|July 20, 2023
Pansclerotic morphea is characterized by IFN-γ responses priming dendritic cell fibroblast crosstalk to promote fibrosisEnze Xing, Feiyang Ma, Rachael Wasikowski, et al.
Annals of the Rheumatic Diseases|August 9, 2019
Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signaturesShervin Assassi, Xuan Wang, Guocai Chen, et al.
Nature Communications|January 31, 2023
Author Correction: Fibroblast A20 governs fibrosis susceptibility and its repression by DREAM promotes fibrosis in multiple organsWenxia Wang, Swarna Bale, Jun Wei, et al.
Translational Behavioral Medicine|March 31, 2023
Exploring research team members' and trial participants' perceptions of acceptability and implementation within one videoconference-based supportive care program for individuals affected by systemic sclerosis during COVID-19: a qualitative interview studyAmanda Wurz, Kelsey Ellis, Delaney Duchek, et al.
Arthritis and Rheumatism|November 13, 2002
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trialPaul J DeMarco, Michael H Weisman, James R Seibold, et al.
Pageof 30